Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

BRAF V600E is the key oncogenic driver mutation in hairy cell leukemia (HCL). We report the efficacy and safety of dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive HCL. This open-label, phase 2 study enrolled patients with BRAF V600E mutation–positive HCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreitman, Robert J., Moreau, Philippe, Ravandi, Farhad, Hutchings, Martin, Gazzah, Anas, Michallet, Anne-Sophie, Wainberg, Zev A., Stein, Alexander, Dietrich, Sascha, de Jonge, Maja J. A., Willenbacher, Wolfgang, De Grève, Jacques, Arons, Evgeny, Ilankumaran, Palanichamy, Burgess, Paul, Gasal, Eduard, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163281/
https://www.ncbi.nlm.nih.gov/pubmed/36108341
http://dx.doi.org/10.1182/blood.2021013658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163281/
https://www.ncbi.nlm.nih.gov/pubmed/36108341
http://dx.doi.org/10.1182/blood.2021013658

Ejemplares similares